What GLP-1 Does OptumRx Cover in 2026?

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The short answer

What GLP-1 does OptumRx cover? Its current 2026 standard sources show 12 preferred GLP-1 or GLP-1-containing drug-and-form groups: Wegovy injection, Wegovy tablets, Wegovy HD, the Zepbound single-dose auto-injector, Saxenda, and Foundayo for weight management; plus Ozempic injection, Ozempic tablets, Rybelsus, Mounjaro, Trulicity, and Soliqua for type 2 diabetes. Eleven of the 12 carry prior authorization in the source that establishes their current status. Three things still change your answer: which list your plan uses, which form is on your prescription, and whether your employer bought the weight-loss benefit at all.

Here's the part almost nobody tells you.

Four current Tier 2 drug-and-form groups — Wegovy tablets, Wegovy HD, Ozempic tablets, and Foundayo — are not separately printed in the July formulary booklets. If you downloaded a booklet, searched your exact drug, and got nothing, you may have read the wrong document. We’ll show you where the current answer lives.

Best for you if: your pharmacy card says Optum Rx — whether your insurer is UnitedHealthcare or not — and you want to know which drug and form to ask about before your appointment.

Not for you if: you already know your drug is covered and just need the paperwork approved. Start with our GLP-1 insurance approval guide instead. If your card says UnitedHealthcare and you want the whole plan picture, start with What GLP-1 Does United Healthcare Cover.

What we actually verified

We opened 11 Optum Rx documents on Optum's own website on August 12, 2026:

• The Select Standard formulary booklet effective July 1, 2026
• The Premium Standard formulary booklets effective January 1 and July 1, 2026, so we could compare versions
• The Select and Premium prior authorization lists effective July 1, 2026
• The Select and Premium step-therapy lists effective July 1, 2026
• Pharmacy Passages for February, April, May, and July 2026 — Optum Rx's monthly change log

We also read Optum-hosted pages for two FedEx plans, current VA guidance for CHAMPVA, current CMS Medicare guidance, FDA approval records and labels, a Michigan external-review decision, and the current public pages for every provider we mention. Optum describes Pharmacy Passages as its monthly record of changes involving exclusions, tiers, prior authorization, quantity limits, and step therapy.

What we cannot tell you, and neither can any other website:

• Whether your employer bought the weight-loss drug benefit
• Your copay or deductible
• The exact approval rules attached to your plan
• Whether your request will be approved
• Whether any GLP-1 is medically right for you

Optum Rx says your benefit-plan documents control whenever they differ from the standard list.

Our honest limitation, up front: we can't turn the word "OptumRx" into your personal yes or no. Nobody can. What we can do is show you exactly what Optum Rx printed, which document to trust for which drug, and the one question that gets you a real answer in a single phone call. That question is further down, and it's the most useful thing on this page.

One safety note before we go on. Several medicines on this page, including Wegovy, Zepbound, and Foundayo, have FDA-labeled warnings and contraindications involving medullary thyroid carcinoma and MEN 2. A licensed clinician decides whether a GLP-1 is appropriate for you. See our GLP-1 contraindications guide. This page helps you find the covered option to discuss. Your doctor decides the right one.

Why can’t I find weight-loss GLP-1s in the OptumRx booklet?

Optum Rx's formulary booklets have no category called weight loss, obesity, or GLP-1. Wegovy injection, the Zepbound auto-injector, and Saxenda are filed under "Central Nervous System Agents – Miscellaneous." Ozempic and Mounjaro sit under "Diabetes – Antidiabetic Agents." If you scanned the table of contents looking for "weight loss," that's why you came up empty.

We're starting here because it's the thing that makes people feel stupid, and it isn't their fault.

Optum Rx uses four different naming systems for these drugs across its own documents:

The prior authorization list is the Optum Rx document that files these medicines under the two headings most people would actually search: "Weight Loss" and "GLP-1 Agonists." But a drug appearing on that list does not, by itself, prove that your formulary covers it. We’ll show you why below.

One more thing you can check in five seconds. The May 2026 Pharmacy Passages lists Foundayo's generic name twice, in two different tables, spelled two different ways — “oforglipron” and “orfoglipron.” The correct spelling is orforglipron. So if you search that PDF for the correct name, you get zero hits on a drug that appears in the document twice.

You weren't doing it wrong. The paperwork is genuinely a mess.

What GLP-1 does OptumRx cover in 2026?

The current standard sources show 12 preferred GLP-1 or GLP-1-containing drug-and-form groups. They also show five excluded, absent, or prior-authorization-only entries that should not be mistaken for confirmed coverage. Most preferred options are Tier 2 and require prior authorization.

This is the table we built, and it's the reason this page exists. Every row traces to a named document with an effective date. Where Optum Rx documents answer different questions, we show you what each one proves instead of blending them together.

The weight-management lane

The two Wegovy tablet rows represent one drug-and-form group with a separate starter-dose limit. That is why the page counts six preferred weight-management groups, not seven.

The type 2 diabetes lane

Ozempic tablets are counted as one drug-and-form group. Soliqua is included because it contains the GLP-1 medicine lixisenatide, but it is a fixed-dose insulin combination for diabetes — not a stand-alone GLP-1 and not a weight-loss substitute.

Entries that do not prove current standard coverage

This distinction matters: a prior authorization list tells you the rules Optum may apply if a claim is eligible for coverage. It is not a second formulary. Victoza, exenatide, and other entries prove that the PA list can contain medicines that the Premium booklet excludes or the Select booklet never names.

Sources: Optum Rx July 2026 Select and Premium Standard Formularies; January 2026 Premium Standard Formulary for version comparison; July 2026 Select and Premium prior authorization lists; and Pharmacy Passages for February, April, May, and July 2026. Your plan may use a customized list. Medicare, Medicaid, and CHAMPVA follow separate rules — covered further down.

What the codes mean, in plain words

• Tier 2 — the second covered tier on these standard lists. Your employer or plan sets the actual dollar amount.
• PA (prior authorization) — your prescriber must give the plan the information required to approve the drug for your use.
• QL (quantity limit) — a cap on how much you can receive or how often you can refill it.
• ++ (benefit design) — Optum Rx's legend says: “Coverage is determined by your prescription medication benefit plan.”
• Excluded / Tier E — not covered on that standard list unless your plan grants an exception.

Four things in those tables you won't find on a normal drug-list page

1. The Wegovy tablet starter cap allows two full 30-day starts per 365 days.

WEGOVY TAB and WEGOVY TAB 1.5 MG both appear by name on the July 2026 prior authorization lists. The regular tablet limit is one per day. The 1.5 mg starter dose is capped at 60 tablets per 365 days.

The FDA-labeled oral Wegovy schedule uses 1.5 mg once daily for the first 30 days. Sixty tablets therefore equals two full 30-day starts. If you stop and need a third restart inside the same 365-day period, the standard starter limit has already been used unless the plan approves an override.

1. The Ozempic quantity limit is one device unit a month — not four weekly units.

The PA list prints “1 syringe per 28 days” for Ozempic. Several weekly injectables on the same list are capped at four syringes per 28 days. Ozempic uses a multidose pen, so the monthly unit is different. If someone tells you the standard limit is four Ozempic pens, they're reading a different row.

1. Being on the PA list does not mean a drug is covered.

Victoza appears in authorization material while the Premium booklet marks it excluded. Exenatide appears in authorization material while Premium marks it excluded. Bydureon BCise appears on the Select PA list while neither current standard booklet names it.

That is why this page does not call those drugs covered. The formulary tells you the drug's list status. The PA document tells you what rules may apply if the claim is otherwise eligible.

1. Soliqua is the only GLP-1-containing product in the current standard booklets with no PA, QL, ST, or SP notation.

It is a fixed-dose combination of long-acting insulin and lixisenatide. It is a diabetes medicine — not a weight-loss drug and not a substitute for Wegovy or Zepbound. We're flagging it because it proves the rules are applied product by product, not with one blanket rule for everything that contains a GLP-1 medicine.

🔎 Not sure which row is yours?

Run your own result through the free five-minute check below. You’ll identify your plan lane, exact drug and form, portal result, and the one benefit question that the public list cannot answer.

Use the five-minute OptumRx coverage check →

You do not need to share your member ID, date of birth, or diagnosis with us.

Why do two people with OptumRx get different answers?

Optum Rx runs the pharmacy benefit, but your employer or plan sponsor decides which benefits it bought and which plan documents apply. That's why two people can both hold an Optum Rx card, see the same Tier 2 listing, and get opposite answers on the same medicine.

Every weight-management GLP-1 printed in the current booklets — Wegovy injection, Saxenda, and the Zepbound single-dose auto-injector — carries the ++ flag. Optum Rx defines it this way:

++ Benefit design options — “Coverage is determined by your prescription medication benefit plan.”

The midyear update tables that added Wegovy tablets, Wegovy HD, and Foundayo do not include a ++ column. We therefore cannot claim that those three rows carry that exact code. They still remain subject to your plan documents.

No diabetes GLP-1 printed in the current standard booklets carries the ++ flag.

So there are two layers of “covered” in the same set of documents:

Picture two workers at different companies. Both have Optum Rx. Both see Wegovy at Tier 2. One gets the plan's covered copay. The other is told weight-management drugs are excluded and is shown the full cash price.

Neither one is necessarily misreading the document. Their plans bought different benefits.

Same PBM, completely different answer — three real examples

This is the part that turns an abstract idea into something you can act on. We pulled three benefit arrangements that use Optum Rx and landed somewhere different.

The current CHAMPVA guidance is more specific than a simple “weight drugs excluded” statement. It says Ozempic, Mounjaro, Rybelsus, Trulicity, and Victoza may be covered for type 2 diabetes. It also describes Zepbound coverage for moderate-to-severe obstructive sleep apnea and Wegovy coverage for qualifying cardiovascular-risk reduction or MASH uses, with prior authorization where required.

Look at the two FedEx rows again. Same company. Same PBM. Both require a named program. Yet the examples on the two plan pages are not identical.

The practical lesson: if your plan requires enrollment in a named program, no amount of telehealth spending skips that step. Confirm and complete the program requirement before paying someone to file paperwork.

Conflicting answers are built into this system because the standard list, employer benefit, diagnosis, form, and prior authorization can each answer a different part of the question. If you've felt jerked around, you were not imagining the conflict.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with current pricing before you choose.

What it asks: your state, insurance situation, medication preference, budget, and support needs What you get: a shortlist matched to your situation, with pricing and the exact questions to ask Cost: free · about 2 minutes · no signup

Get my personalized GLP-1 action plan →

Does the GLP-1 form change whether OptumRx covers it?

Yes. Optum Rx's July 2026 Premium list names three separate Zepbound products. The single-dose auto-injector is Tier 2 and preferred. The vial is excluded. The KwikPen is excluded. Same active medicine, three different commercial-list answers.

The three Zepbound forms

Here's the finding that took two document versions to see. On the January 1, 2026 Premium list, the KwikPen was not separately named. On the July 1, 2026 Premium list, ZEPBOUND KWIKPEN appears as its own line — marked excluded.

Same formulary series. Different effective dates. The cover date is what tells you which version you have.

So check the date on your PDF before you trust it.

And the practical takeaway: if your Zepbound claim was rejected, the problem may be the form rather than the whole medicine. If your clinician agrees that the preferred form fits your care, the change may be handled with a new prescription instead of a full appeal.

Wegovy: injection, tablet, and the higher dose

The July prior authorization lists name WEGOVY INJ, WEGOVY TAB, and WEGOVY TAB 1.5 MG separately, with different quantity limits. The standard booklet does not separately print the tablet products. Wegovy HD 7.2 mg appears in the April 2026 update at Tier 2 and is not separately named in the July booklet either.

What to do about it: search the exact product name, strength, and form in your member account. Not just the brand. If the form is unclear, ask your pharmacy for the National Drug Code tied to the exact drug, strength, and package, then use that code when you call.

A broad “yes, Wegovy is covered” can hide a form-specific answer. The exact product identifier cannot.

Are Foundayo, the Ozempic pill, Wegovy tablets, and Wegovy HD covered?

All four are Tier 2 on both standard lists through dated Optum Rx updates, with prior authorization and a quantity limit. None is separately printed in the current July formulary booklets. If you searched only the booklet and found nothing, the monthly update is the document you were missing.

This is the single most useful thing on this page, so let's be precise about it.

Where the answer lives instead: a monthly Optum Rx publication called Pharmacy Passages. It records exclusions, tier changes, new drugs, prior authorization, quantity limits, and step-therapy changes between full booklet editions.

Foundayo's real timeline, and why people got different answers

Foundayo was FDA-approved on April 1, 2026. Then:

April 3, 2026 — Optum Rx initially placed it at Tier 3 on Select and excluded on Premium, with PA and QL. May 11, 2026 — Optum Rx moved it to Tier 2 on both lists, with PA and QL.

That initial split lasted 38 days — about five and a half weeks.

Optum Rx says medicines placed on its new-drug exclusion list can remain excluded for up to six months. Foundayo moved off Premium's exclusion status much sooner than that.

Full transparency on one wrinkle: Foundayo is still not named on the July prior authorization lists, so those documents do not give us a numerical quantity limit. The May change log itself establishes Tier 2, PA, and QL status. Verify the exact product in your member tool before you count on it.

And the pattern worth remembering: if a medicine was added or approved during the year and you can't find it in the twice-yearly booklet, check the monthly update before you conclude it is excluded.

We also found that Foundayo's first published status was different by standard list: Select began at Tier 3 while Premium began excluded. That is one reason people could have received opposite answers only weeks apart.

See our full OptumRx Foundayo coverage guide for that drug specifically.

Does OptumRx require step therapy for GLP-1s?

Not on the current Select or Premium standard sources we reviewed. Optum Rx defines an ST code and publishes separate July 2026 step-therapy lists, but none of the relevant GLP-1 product names appears in either current step-therapy document. The current formulary rows for these preferred products also carry no ST mark.

This matters because it's one of the most common claims made about this topic.

The absence counts as real evidence because Optum Rx has a defined step-therapy code, uses it on other medicines, and publishes dedicated step-therapy lists. The current standard GLP-1 rows simply are not marked that way.

Same for the specialty flag. None of the relevant preferred GLP-1 rows carries SP on the current standard booklets. That means the current Select and Premium standard sources do not support a blanket claim that all Optum Rx GLP-1s sit on a specialty tier.

The honest limits, because scope matters here:

This covers the two standard commercial lists. A customized employer list can add different requirements. State Medicaid programs administered by Optum Rx can use their own criteria. A program requirement — like Calibrate for the FedEx examples — is not step therapy, but it can still block coverage until you complete it.

If you were told you have to fail a cheaper medicine first, ask which plan document says so and request the rule in writing. On the current standard sources we reviewed, it isn't there. If your customized plan genuinely does require a first-step medicine, our GLP-1 insurance approval guide walks through the exception path.

How do I check my own OptumRx coverage before my doctor sends anything?

Log into the member account tied to your pharmacy benefit, search each medicine by exact name and form, save what you see, then call and ask the one question the public document can't answer. Five minutes here can save you weeks.

The five-minute check

Step 1 — Figure out which lane you're in. Employer or commercial plan. Medicare Part D. CHAMPVA or another government program. The lanes have different answers and the rest of this only works if you know yours.

Step 2 — Confirm Optum Rx is your current pharmacy benefit manager. Look on your card for “Optum Rx” or “OptumRx,” plus RxBIN, RxPCN, or RxGRP information. Sometimes pharmacy benefits appear on a separate card from medical benefits.

Step 3 — Search the exact product, not just the brand. Search “Wegovy injection.” Then “Wegovy tablet” and the strength. Search “Zepbound auto-injector,” “Zepbound vial,” and “Zepbound KwikPen” separately. Do the same for the diabetes product that applies to you.

Step 4 — Save six things.

Covered, excluded, or not found The tier Any PA, QL, or ST notation The estimated price at your pharmacy The exact product, strength, and form Today's date

Take a screenshot. It is a dated record of what your member tool showed — useful if a later answer is different.

Step 5 — Call and ask these five questions.

Is this exact drug and form covered on my plan? For which diagnosis or FDA-approved use is it covered? Does it need prior authorization, a quantity limit, or step therapy? Does my plan include the weight-management drug benefit at all, and does it require enrollment in a named program first? What will I pay at my pharmacy before and after my deductible?

Question 4 is the ++ question. It's the one most people never ask, and it's the one that can decide everything.

Step 6 — Hand your prescriber the exact words.

“My plan shows [exact product and form] as [what the portal said], with [PA / QL / ST]. Please write it for that exact form and request my plan's current prior-authorization criteria before submitting.”

If you need medicine before the paperwork clears

Optum Rx publishes a short-term option on its prior authorization documents:

Ask your doctor whether a sample is available. You can also ask your pharmacy whether a short-term supply of five days or less is allowed while the prior authorization is pending. You pay the full cost for that small supply. If the request is later approved, the pharmacist may be able to fill the rest of the prescription.

That's not a loophole. It's printed in the document. Your pharmacy and plan still decide whether it can be used for your prescription.

📄 Keep this checklist open at your appointment

It gives you the exact information to save, the five questions to ask, and the wording to hand your prescriber. For the next steps after a PA or denial, use our full insurance guide.

Open the GLP-1 insurance approval guide →

Am I on the Premium list or the Select list — and does it matter?

Optum Rx runs two standard commercial lists. They agree on every GLP-1 they both print. A major difference is how exclusions appear: Premium prints excluded products with a Tier E mark, while Select may leave excluded products out. So “I couldn't find my drug” still does not give you a personal yes or no.

Write this down: a medicine missing from a published list proves the list doesn't name it. It does not prove your own plan excludes it.

That distinction is the difference between giving up and making one phone call.

How to tell which one you have: check the cover page of your formulary PDF, the footer document code, or ask the representative when you call. Many employers use a customized list that is neither standard version. If yours does, the standard lists are useful context — but your plan's own member result and benefit documents govern.

Why did OptumRx deny a GLP-1 that showed as covered?

A listed drug can still be rejected because the prior authorization was missing or incomplete, the exact form is excluded, the diagnosis or use does not meet the plan's rule, a quantity limit was hit, a step or program requirement applies, or your employer excluded the benefit. Get the exact reason in writing before you change medicines or reach for your credit card.

We want to be straight with you about something the older version of this page got wrong: not every denial is a paperwork problem. Missing paperwork can be fixed. A benefit exclusion often cannot be changed in the middle of the plan year. Telling you otherwise would waste your time.

Match your reason to your move:

Missing paperwork is the most fixable category. A PA can fail when the office leaves out something the current criteria require. Ask for the exact criteria. Submit the chart details those criteria request instead of relying on a generic “medically necessary” note.

A line we won't cross: don't chase a diagnosis you don't have. Ozempic and Mounjaro are diabetes-labeled medicines. Trying to put an inaccurate diagnosis in your record to force a weight-loss approval is the wrong lane. Match the request to the real reason you're taking it.

A real case, from the public record

This is a public administrative decision, not a customer review — and it's the most instructive coverage story we've found.

Michigan's Department of Insurance and Financial Services decided external-review File No. 244942-001-SF on March 25, 2026. The decision names OptumRx, Inc. as the plan administrator.

During 2025 open enrollment, the member's plan announced that starting January 1, 2026, GLP-1s would no longer be covered for weight management and existing authorizations for that use would end December 31, 2025. Then, on November 10, 2025, Optum Rx approved an authorization with an expiration date of November 10, 2026.

Her January refill rejected. She filed a grievance, lost, and took it to external review. The Director upheld the denial: the plan documents controlled, and the later date printed on the authorization did not survive the plan-wide benefit change.

Her own words in the record: “disappointed, discouraged and tired.”

The lesson is the useful part. She said that if she'd understood the change during open enrollment, she would have considered opening an FSA or changing plans. By January, that window was shut.

So: if you hold an approval that crosses into the next plan year, verify it during open enrollment — not after the new year starts.

Different plan, different employer. It doesn't predict your outcome. It shows you exactly how a plan-wide benefit change can overrule an authorization date — and where the one decision window was.

✉️ Denied? Start with the written reason

Do not send a generic appeal before you know whether the problem is missing information, the exact form, a quantity limit, a program rule, or a benefit exclusion.

Use the GLP-1 insurance and appeal guide →

What if I have Medicare Part D with OptumRx?

Do not use the commercial Select or Premium lists as your final answer. The Medicare GLP-1 Bridge began July 1, 2026 and runs through December 31, 2027. It is a separate federal pathway with its own product list, clinical rules, and a $50 copay for an eligible 30-day supply.

The Bridge includes:

• All Foundayo products
• Wegovy injection products
• Wegovy tablet products
• Zepbound KwikPen products

CMS states that Zepbound single-dose vials and single-dose pens are not available through the Bridge.

Read that next to the commercial Premium list:

Exactly backwards. A person moving from a commercial Optum Rx standard plan to an eligible Part D Bridge path may need the opposite Zepbound device. The form that worked under the commercial benefit can reject under the Bridge.

If your Medicare drug coverage is about to start, have that conversation with your prescriber before the coverage change.

The Bridge has its own eligibility and prior-authorization rules. It also sits outside the normal Part D benefit: the deductible does not apply, and the $50 copay does not count toward Part D true out-of-pocket spending.

Start with our Medicare GLP-1 Bridge guide. It covers eligibility, the separate covered-use rules, and what to check if you already take one of these medicines.

Two more lanes worth naming. State Medicaid programs administered by Optum Rx use their own state criteria, so see what GLP-1 does Medicaid cover. Optum's monthly commercial update files also refer to “Direct and UMR,” but a UMR plan can still be customized. UMR members should use the exact member result rather than assume every standard-list row applies.

What if my plan excludes the GLP-1 my doctor recommended?

First find out what the exclusion actually covers — the whole benefit, one form, one use, or one product. Those have different fixes. Then work the simplest and least costly paths before you reach for a credit card.

1. Ask whether a different form is covered. If the KwikPen is excluded and the single-dose auto-injector is Tier 2, that's not necessarily an appeal — it may be a new prescription. Your clinician decides whether the other form is appropriate for you.

1. Ask whether a separate FDA-approved use you already have follows a different coverage lane. Wegovy and Zepbound have FDA-approved uses beyond chronic weight management. Zepbound has an obstructive sleep apnea indication for qualifying adults with obesity. Wegovy has qualifying cardiovascular-risk-reduction and MASH indications. A plan may treat those uses differently.

Guardrail: this only works when the condition is real, documented, and fits the exact labeled use and plan rule. Do not go shopping for a diagnosis.

1. Request a formulary exception. Optum Rx says you, your authorized representative, or your doctor can start a coverage request by calling the number on your ID card. If the exception is approved, you may be able to fill an excluded medicine, though your cost can be higher.

1. Ask HR two questions. Ask whether the weight-management benefit can be added at renewal and whether an FSA would help before the enrollment window closes. That's the door the Michigan member above wished she'd found during open enrollment.

1. Compare manufacturer-direct cash programs. LillyDirect and NovoCare offer direct cash-pay routes for certain brand-name GLP-1 products. We earn nothing when you use them. Depending on the medicine, dose, and current terms, manufacturer direct may be the lowest no-membership brand-name route. Compare the exact current price and eligibility before paying a telehealth membership.

Current prices and fees are in our GLP-1 cost without insurance guide.

A hard line on compounded products. Compounded semaglutide and tirzepatide are not FDA-approved, they do not appear as covered products on either Optum Rx standard formulary, and they are not FDA-approved generic versions of Wegovy, Zepbound, Ozempic, or Mounjaro. They are a separate cash-pay treatment path with different sourcing, quality, labeling, and legal questions. Don't let anyone blur the two for you.

If you want to understand that path on its own terms, read compounded vs. name brand.

Where does Ro fit if you have OptumRx?

Ro is a fit when you'd rather have a telehealth team handle the insurance paperwork. It supports insurance access for FDA-approved pen products including the Zepbound auto-injector — the form preferred on Optum Rx's commercial standard lists — and offers a free coverage checker that contacts your insurer and returns a personalized report before you join.

One honest thing before you click

Ro's free coverage checker does not cover every GLP-1 form. It checks the Ozempic pen, Wegovy pen, and Zepbound pen. It does not check the Zepbound KwikPen, Foundayo, or Wegovy tablets.

So if you're on the KwikPen, or you want Foundayo or a Wegovy tablet, Ro's checker won't give you your answer — start with your OptumRx member account instead, using the five-minute steps above.

And if all you want is the lowest current cash price on a brand name and you're willing to handle the insurance work yourself, compare LillyDirect or NovoCare before paying a membership fee. That's a fair call and we won't argue with it.

But here's why Ro's checker can still help. It contacts the insurer and gives you a written coverage and cost report without issuing a prescription. If you later join Ro and qualify, its insurance concierge can verify benefits, submit prior authorization, help with an appeal, and evaluate another clinically appropriate covered option.

This is not an instant approval service. Ro says its full insurance process generally takes about two to three weeks, with the prior-authorization part often taking one to two weeks.

Ro Body pricing: $39 for the first month, then as low as $74 per month with an annual plan paid upfront, or $149 month-to-month. The membership covers clinical visits, ongoing care, eligible labs ordered through the program, and the insurance-support team. The medicine is billed separately.

Does that sound like your situation?

Check coverage free for an Ozempic, Wegovy, or Zepbound pen with Ro → (sponsored affiliate link · opens in a new tab)

Free report, not a prescription. Medicine is billed separately. The checker supports three pen products. Government-plan eligibility is limited.

Want to pick your own clinician instead? Sesame Care (sponsored) lets you choose your provider and publishes cash-pay branded options. Ongoing care starts as low as $59 per month with an annual subscription; medication is separate.

Who should not start online first: anyone with a medical emergency, an unstable or complex condition, a possible contraindication, or who is pregnant or trying to become pregnant — and anyone whose plan requires their primary doctor or a specialist to start treatment. Start with your own clinician.

How we built this page

We read 11 Optum Rx documents on Optum's own website on August 12, 2026 and recorded exactly what each one printed, including the effective date and document type. Where two documents answered different questions, we kept those answers separate. Where we couldn't verify something, we left it out and said so.

Our source order, strongest first

Your own current member result — nothing beats it An Optum-hosted document for your specific employer or government plan The current Select or Premium formulary booklet A dated Pharmacy Passages update for a midyear change The current prior authorization and step-therapy lists CMS, VA, FDA, or a state agency for government, regulatory, and public-record claims A provider's own current page for provider-specific pricing and service claims

For every drug we recorded: name, form, strength where given, use lane, Select status, Premium status, PA, QL, ST, ++, SP, exclusion status, exact quantity limit where printed, the source effective date, our verification date, and the member-level limit on what the source proves.

What we chose not to publish, and why

• No universal copay figures. Your employer or plan sets the dollar amount.
• No universal prior-authorization criteria. Your plan's exact criteria are what get applied.
• No approval-odds statistic. We do not have a reliable Optum Rx GLP-1 approval dataset.
• No prior-authorization turnaround promise. Timing depends on the plan, urgency, completeness, and provider.
• No unverified forum quotations. Individual stories can explain confusion, but they cannot establish policy.
• No inference that PA-list placement proves coverage. The current documents show that it does not.
• No stale cash-price table. Prices change too fast. We route readers to the separately maintained cost guide instead.

Version history

Frequently asked questions

Does OptumRx cover GLP-1 medications?

Yes. The current 2026 standard sources show 12 preferred GLP-1 or GLP-1-containing drug-and-form groups for weight management or type 2 diabetes. Eleven carry prior authorization in the source establishing their current status. Your own benefit, diagnosis, exact form, and plan documents still decide whether your claim is paid.

Does OptumRx cover Wegovy?

The current standard sources place Wegovy injection, Wegovy tablets, and Wegovy HD at Tier 2 with prior authorization and quantity limits. The injection also carries the ++ benefit-design flag in the booklets. Your plan still decides whether it includes weight-management drug coverage.

Does OptumRx cover the Wegovy pill?

Yes on the current standard sources. Wegovy tablets moved to Tier 2 on both Select and Premium effective February 15, 2026, with PA and QL. The July PA lists cap the standard tablet at one per day and the 1.5 mg starter dose at 60 tablets per 365 days.

Does OptumRx cover Zepbound?

It depends on the form. On the July Premium standard list, the single-dose auto-injector is Tier 2 with PA, QL, and ++. The vial and KwikPen are marked excluded. The Select booklet names the preferred auto-injector but does not separately name the vial or KwikPen.

Does OptumRx cover the Zepbound KwikPen?

Not on the July 2026 Premium commercial standard list, where it is marked excluded. It is not separately named on Select. The Medicare GLP-1 Bridge is the opposite: it includes the KwikPen and does not include the single-dose pen or vial.

Does OptumRx cover Foundayo?

Optum Rx's May 2026 update places Foundayo at Tier 2 on both standard lists with PA and QL, effective May 11, 2026. It is not separately printed in the July booklets or named in the July PA lists, so no exact quantity amount is publicly printed there. Verify it by exact product name in your member account.

Does OptumRx cover Ozempic for weight loss?

Ozempic is listed in the diabetes lane, and its FDA label is not a chronic weight-management label. The current Optum PA list gives the injection a limit of one syringe per 28 days. A weight-loss-only request is not the same coverage lane as a type 2 diabetes request.

Is Mounjaro covered for weight loss through OptumRx?

Mounjaro is listed in the diabetes section at Tier 2 with PA and a limit of four syringes per 28 days. Mounjaro is the diabetes-labeled tirzepatide product. Zepbound is the tirzepatide product with weight-management and qualifying obstructive-sleep-apnea indications.

Does OptumRx require step therapy for GLP-1s?

Not on the current Select or Premium standard sources we reviewed. The relevant product names do not appear on the July 2026 standard step-therapy lists, and the preferred formulary rows do not carry an ST mark. A customized employer plan or state Medicaid program can differ.

What does ++ mean on the OptumRx drug list?

It is Optum Rx's benefit-design flag. The legend says coverage is determined by your prescription medication benefit plan. The weight-management GLP-1s printed in the current booklets carry it. The midyear update tables do not include a ++ field, so the code cannot be assigned from those tables alone.

Does appearing on the OptumRx PA list mean a drug is covered?

No. The current PA material contains products that the Premium booklet marks excluded or that the Select booklet does not name. Use the formulary or member account for list status. Use the PA document for authorization rules and quantity limits.

Why can't I find my GLP-1 on the OptumRx formulary?

Four common reasons:

The weight medicines are not filed under a “weight loss” section in the booklet. Select can leave excluded products out instead of printing them. Wegovy tablets, Wegovy HD, Ozempic tablets, and Foundayo were added or changed through midyear updates and are not separately named in the July booklet. Your employer may use a customized list.

Is OptumRx the same as UnitedHealthcare?

No, though they are related. UnitedHealthcare is a health insurance company. Optum Rx is a pharmacy benefit manager. Both are part of UnitedHealth Group. Optum Rx also administers pharmacy benefits for plans that are not UnitedHealthcare plans.

What's the difference between the Premium and Select lists?

They agree on the preferred GLP-1s they both print. Premium often prints excluded products with a Tier E mark, while Select may leave them out. That is why a missing product on Select cannot be treated as proof of coverage or proof of exclusion.

Can I get an exception if my plan excludes a GLP-1?

Sometimes. Optum Rx says you, your authorized representative, or your doctor can start a coverage request using the number on your ID card. A product-level formulary exception is different from an appeal against a plan-wide benefit exclusion. A whole-category exclusion is usually the harder problem.

Does OptumRx cover compounded semaglutide?

Do not assume it does. Compounded semaglutide and tirzepatide are not FDA-approved and do not appear as covered drug products on either Optum Rx standard formulary. They are not FDA-approved generic versions of Wegovy, Zepbound, Ozempic, or Mounjaro and are generally offered through separate cash-pay programs.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz. It asks about your state, insurance situation, medication preference, and budget — then gives you a shortlist with current pricing and the exact questions to ask.

Take the free 60-second GLP-1 matching quiz →

Sources

• Optum Rx 2026 Select Standard Formulary, effective July 1, 2026
• Optum Rx 2026 Premium Standard Formulary, effective January 1, 2026
• Optum Rx 2026 Premium Standard Formulary, effective July 1, 2026
• Optum Rx Select Formulary Prior Authorization Utilization Management List, effective July 1, 2026
• Optum Rx Premium Formulary Prior Authorization Utilization Management List, effective July 1, 2026
• Optum Rx Select and Premium Step Therapy Utilization Management Lists, effective July 1, 2026
• Optum Rx Pharmacy Passages, February, April, May, and July 2026
• Optum-hosted benefit pages for FedEx and FedEx Surest
• U.S. Department of Veterans Affairs — current CHAMPVA GLP-1 guidance
• Centers for Medicare & Medicaid Services — Medicare GLP-1 Bridge and Information for Part D Plans
• FDA approval announcements and current prescribing information for Wegovy, Zepbound, Ozempic, Rybelsus, Mounjaro, Trulicity, Saxenda, Victoza, Soliqua, and Foundayo
• FDA guidance and enforcement notices concerning compounded GLP-1 products
• Michigan Department of Insurance and Financial Services — external-review File No. 244942-001-SF, March 25, 2026
• Current public coverage, pricing, testimonial-disclosure, cancellation, and subscription pages for Ro
• Current public weight-management membership page for Sesame Care

Last verified August 12, 2026. Next full review: January 2027, when the next formulary cycle publishes. We check Pharmacy Passages monthly.

This page is information, not medical advice. Only a licensed clinician can decide whether a GLP-1 is appropriate for you. Coverage and pricing change. Always confirm against your own current plan documents before making a decision.

Related reading

• OptumRx Zepbound Prior Authorization: 8 Fixes
• Does OptumRx Cover Foundayo?
• [GLP-1 Providers That Accept OptumRx](/guides/glp-1-providers-that-accept-optumrx/)
• [What GLP-1 Does United Healthcare Cover?](/guides/what-glp-1-does-united-healthcare-cover/)
• GLP-1 Formulary Tier Explained
• Medicare GLP-1 Bridge: $50 Through December 2027
• GLP-1 Cost Without Insurance: Current Prices